103 related articles for article (PubMed ID: 25680731)
1. Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas.
Jabehdar Maralani P; Melhem ER; Wang S; Herskovits EH; Voluck MR; Kim SJ; Learned KO; O'Rourke DM; Mohan S
Eur Radiol; 2015 Sep; 25(9):2738-44. PubMed ID: 25680731
[TBL] [Abstract][Full Text] [Related]
2. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging.
Wang S; Kim S; Chawla S; Wolf RL; Knipp DE; Vossough A; O'Rourke DM; Judy KD; Poptani H; Melhem ER
AJNR Am J Neuroradiol; 2011 Mar; 32(3):507-14. PubMed ID: 21330399
[TBL] [Abstract][Full Text] [Related]
3. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
[TBL] [Abstract][Full Text] [Related]
4. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
[TBL] [Abstract][Full Text] [Related]
5. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
[TBL] [Abstract][Full Text] [Related]
6. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
[TBL] [Abstract][Full Text] [Related]
7. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
She D; Xing Z; Cao D
J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
[TBL] [Abstract][Full Text] [Related]
9. Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas.
Thomsen H; Steffensen E; Larsson EM
Acta Radiol; 2012 Feb; 53(1):95-101. PubMed ID: 22114021
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-Searching for a practical approach.
Neska-Matuszewska M; Bladowska J; Sąsiadek M; Zimny A
PLoS One; 2018; 13(1):e0191341. PubMed ID: 29342201
[TBL] [Abstract][Full Text] [Related]
12. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
13. Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma.
Ulmer S; Liess C; Kesari S; Otto N; Straube T; Jansen O
J Neurooncol; 2009 Jan; 91(2):213-20. PubMed ID: 18807224
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion.
Bauer AH; Erly W; Moser FG; Maya M; Nael K
Neuroradiology; 2015 Jul; 57(7):697-703. PubMed ID: 25845813
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
[TBL] [Abstract][Full Text] [Related]
16. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
[TBL] [Abstract][Full Text] [Related]
17. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
[TBL] [Abstract][Full Text] [Related]
18. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of cerebral tumors using multi-section echo planar MR perfusion imaging.
Preul C; Kühn B; Lang EW; Mehdorn HM; Heller M; Link J
Eur J Radiol; 2003 Dec; 48(3):244-51. PubMed ID: 14652141
[TBL] [Abstract][Full Text] [Related]
20. MR perfusion in and around the contrast-enhancement of primary CNS lymphomas.
Blasel S; Jurcoane A; Bähr O; Weise L; Harter PN; Hattingen E
J Neurooncol; 2013 Aug; 114(1):127-34. PubMed ID: 23695516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
